Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula:
wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.
The present invention provides a compound represented by the formula (I):
wherein each symbol is as defined in the specification, or a salt thereof.
本发明提供了一种由以下公式(I)表示的化合物:其中每个符号如规范中定义的,或其盐。
[EN] HSD17B13 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE HSD17B13 ET LEURS UTILISATIONS
申请人:METACRINE INC
公开号:WO2022072491A1
公开(公告)日:2022-04-07
Described herein are compounds that are HSD17B13 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with HSD17B13 activity.
4-hydroxy-2,3,5-trifluorobenzoic acid and a process for its preparation
申请人:Hoechst Aktiengesellschaft
公开号:US05446198A1
公开(公告)日:1995-08-29
The present invention relates to the novel compound 4-hydroxy-2,3,5-trifluorobenzoic acid and to a process for preparing this novel substance by reacting 2,3,4,5-tetrafluorobenzoic acid at elevated temperature with a basic compound dissolved and/or suspended in water, adding, if desired, a fluoride scavenger, bringing the resulting reaction mixture to a pH of 0 to 6 by addition of an acid, and isolating the 4-hydroxy-2,3,5-trifluorobenzoic acid formed.